Your browser doesn't support javascript.
loading
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi, Kazuo; Toyoda, Masao; Hatori, Nobuo; Tsukamoto, Shunichiro; Kimura, Moritsugu; Sakai, Hiroyuki; Furuki, Takayuki; Chin, Keiichi; Kanaoka, Tomohiko; Aoyama, Togo; Umezono, Tomoya; Ito, Shun; Suzuki, Daisuke; Takeda, Hiroshi; Degawa, Hisakazu; Hishiki, Toshimasa; Shimura, Hidetoshi; Nakajima, Shinichi; Miyauchi, Masaaki; Yamamoto, Hareaki; Hatori, Yutaka; Hayashi, Masahiro; Sato, Kazuyoshi; Miyakawa, Masaaki; Terauchi, Yasuo; Tamura, Kouichi; Kanamori, Akira.
Afiliação
  • Kobayashi K; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Toyoda M; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
  • Hatori N; Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara.
  • Tsukamoto S; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Kimura M; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
  • Sakai H; Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara.
  • Furuki T; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Chin K; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Kanaoka T; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Aoyama T; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
  • Umezono T; Division of Nephrology, Department of internal medicine, Kitasato University School of Medicine, Sagamihara.
  • Ito S; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Suzuki D; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Takeda H; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Degawa H; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Hishiki T; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Shimura H; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Nakajima S; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Miyauchi M; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Yamamoto H; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Hatori Y; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Hayashi M; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Sato K; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Miyakawa M; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Terauchi Y; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
  • Tamura K; Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kanamori A; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
Cardiovasc Endocrinol Metab ; 12(4): e0292, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37779602

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiovasc Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiovasc Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article